Infinium Pharma (INFINIUM)

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Promoter holding of 64.91% aligns management interests with minority shareholders.
• Piotroski F-Score of 7/9 indicates solid financial health across profitability, leverage, and operational efficiency.
• ROCE of 14.58% shows reasonably efficient capital allocation.
• Profit growth of 26.98% and latest quarterly net profit of ₹7 crore demonstrate earnings momentum.
• Latest quarter net margin of approximately 8.3% is an improvement worth noting.

Concerns

• Sales growth of just 1.29% means profit growth is not backed by topline expansion.
• P/E of 35.26 with PEG of 1.72 leaves limited margin of safety.
• Zero dividend yield offers no income support to valuation.
• Book value, ROE, and debt/equity are not available, so balance sheet strength cannot be properly assessed.

AI Analysis

At ₹329 crore, Infinium Pharma is a small-cap that the market is pricing as a growth stock. The 35.26 P/E is not a Graham bargain. My first discipline is to look for an enduring franchise; the 1.29% sales growth gives me no confidence that this is yet a compounding machine. I do admire the 64.91% promoter holding, which means owners' money is on the line, and a Piotroski score of 7/9 suggests clean financials. The 14.58% ROCE is respectable but not a wide moat. Last quarter's ₹84 crore sales and ₹7 crore net profit imply an 8.3% margin, and the 26.98% profit growth shows cost discipline or operating leverage. However, if sales only grow 1.29%, margin expansion must one day stop. At a PEG of 1.72, I am not being paid enough to take the risk. The absence of dividend forces me to rely wholly on price appreciation, and with no book value or debt/equity data, I cannot assess the balance sheet safety net. I have learnt that a high P/E with low sales growth is a dangerous combination; the market assumes the profit growth is durable. I require a margin of safety. I would pass today, but would monitor whether topline can accelerate. If the company can build scale and maintain margins, this could get more interesting. Until then, this is a 'show me' story.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer